Editorial Director, Addiction & Recovery · Last reviewed January 2025
Benzodiazepines — alprazolam (Xanax), diazepam (Valium), clonazepam (Klonopin), lorazepam (Ativan), and others — are among the most prescribed medications in the United States, widely used for anxiety disorders, insomnia, alcohol withdrawal management, and seizure control. Benzodiazepine use disorder occupies a unique clinical position: it is among the few substance use disorders that are frequently iatrogenic — arising from medically prescribed treatment for legitimate conditions.
How Dependence Develops
Benzodiazepines enhance GABA-A receptor function, producing rapid anxiolysis, sedation, and muscle relaxation. Tolerance to their anxiolytic effects develops within days to weeks of regular use. Physical dependence — characterized by a withdrawal syndrome when use is reduced or discontinued — develops within two to four weeks of regular use at therapeutic doses. This means that patients taking prescribed benzodiazepines daily for a month or more are typically physically dependent, regardless of whether they are experiencing the behavioral features of addiction (compulsive use, craving, loss of control).
Benzodiazepine Withdrawal: Medical Risks
Benzodiazepine withdrawal is medically serious. Like alcohol withdrawal — which shares the same GABA/glutamate mechanism — benzodiazepine withdrawal can cause seizures and delirium. Abrupt discontinuation after prolonged high-dose use is potentially fatal and must never be attempted without medical supervision. The withdrawal syndrome can begin within 6–12 hours for short-acting benzodiazepines (alprazolam, lorazepam) or 24–72 hours for long-acting agents (diazepam, clonazepam), and can persist in a protracted form for weeks to months.
Treatment: Supervised Tapering
The evidence-based treatment for benzodiazepine dependence is supervised tapering — gradually reducing the dose over weeks to months under medical supervision. Typical approaches include switching to a long-acting benzodiazepine (diazepam) for its more gradual, smooth pharmacokinetic profile, then reducing the dose by 5–10% every one to two weeks, with the rate adjusted based on patient response. Concurrent CBT for anxiety is the critical behavioral component — it addresses the underlying anxiety that drove benzodiazepine use and builds coping skills that replace pharmacological anxiolysis.
Co-Occurring Disorders
Because benzodiazepine use disorder typically arises in the context of anxiety disorders, PTSD, or insomnia, addressing these co-occurring conditions is an essential component of treatment. SSRIs/SNRIs are the preferred non-habit-forming pharmacotherapy for anxiety management during and after the taper. See our article on benzodiazepine addiction and mental health for a full dual diagnosis discussion.
Related: Benzo & Mental Health · Anxiety Disorders · Alcohol Use Disorder